Atea Pharmaceuticals, Inc.
AVIR
$6.00
$0.091.52%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 47.60M | 38.23M | 32.35M | 3.44M | 21.15M |
| Gross Profit | -47.60M | -38.23M | -32.35M | -3.44M | -21.15M |
| SG&A Expenses | 7.12M | 7.22M | 9.07M | 9.46M | 13.36M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 54.71M | 45.45M | 41.42M | 39.04M | 34.51M |
| Operating Income | -54.71M | -45.45M | -41.42M | -39.04M | -34.51M |
| Income Before Tax | -51.64M | -41.85M | -36.95M | -34.07M | -33.32M |
| Income Tax Expenses | -6.77M | 196.00K | 207.00K | 203.00K | 225.00K |
| Earnings from Continuing Operations | -44.87M | -42.05M | -37.16M | -34.27M | -33.54M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -44.87M | -42.05M | -37.16M | -34.27M | -33.54M |
| EBIT | -54.71M | -45.45M | -41.42M | -39.04M | -34.51M |
| EBITDA | -54.61M | -45.35M | -41.32M | -38.94M | -34.40M |
| EPS Basic | -0.57 | -0.53 | -0.44 | -0.40 | -0.40 |
| Normalized Basic EPS | -0.41 | -0.33 | -0.28 | -0.25 | -0.21 |
| EPS Diluted | -0.57 | -0.53 | -0.44 | -0.40 | -0.40 |
| Normalized Diluted EPS | -0.41 | -0.33 | -0.28 | -0.25 | -0.21 |
| Average Basic Shares Outstanding | 78.13M | 79.05M | 83.75M | 85.16M | 84.46M |
| Average Diluted Shares Outstanding | 78.13M | 79.05M | 83.75M | 85.16M | 84.46M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |